86 completed, 7 terminated, 4 recruiting, 4 unknown. 105 Phase 1, 11 Phase 2.
Follow Hypercholesterolemia: new trials by email Literature Review of Hypercholesterolemia trials Research Report on Hypercholesterolemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C) Drug: EDIT-401, Placebo - Heterozygous Familial Hypercholesterolemia (HeFH) | Phase 1 / Phase 2 | Not yet recruiting | Editas Medicine, Inc. | 56 | 2026-11-01 | 2026-10-26 |
| A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C) STX-1150 - Elevated LDL-C and High Cholesterol | Phase 1 | Recruiting | Monash University | 64 | 2026-06-30 | 2026-09-21 |
| To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C716 and C716R in Healthy Adults Test Drug, Reference Drug - Hypercholesterolemia, Dyslipidemia | Phase 1 | Completed | AJU Pharm Co., Ltd. | 41 | 2026-06-11 | 2026-07-10 |
| A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults AZD4954, Laroprovstat - Healthy Participants | Phase 1 | Completed | AstraZeneca | 31 | 2026-04-10 | 2026-08-04 |
| Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RN5681 in Healthy Volunteers RN5681, Placebo control - High Cholesterol | Phase 1 | Recruiting | Ikaria Bioscience Pty Ltd | 60 | 2026-03-12 | 2026-04-03 |
| Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets Bempedoic acid film coated tablet, Nilemdo® Film-coated tablets - Hypercholesterolaemia | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 32 | 2025-05-21 | 2025-09-12 |
| To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C711 in Healthy Adults Test Drug, Reference Drug - Hypercholesterolemia | Phase 1 | Completed | AJU Pharm Co., Ltd. | 60 | 2025-03-29 | 2025-06-12 |
| Study of SHR-1209 Administered by Single-site or Multiple-site Subcutaneous Injections in Healthy Volunteers SHR-1209 single-site subcutaneous injection, SHR-1209 multiple-site subcutaneous injections - Hypercholesterolemia and Hyperlipidemia | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 49 | 2025-03-14 | 2026-07-30 |
| A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C. AZD0780, Ezetimibe, Rosuvastatin - Dyslipidemia | Phase 1 | Completed | AstraZeneca | 81 | 2024-12-20 | 2025-11-10 |
| Single Dose Oral Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets in Healthy Adult Human Subjects Under Fasting Conditions. Bempedoic Acid Film Coated Tablet, Nilemdo® (Bempedoic Acid) Film-coated tablets - Hypercholesterolaemia, Mixed Dyslipidaemia | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 14 | 2024-12-04 | 2025-04-11 |
| Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia VERVE-201 - Hypercholesterolemia, Hypertriglyceridemia | Phase 1 | Recruiting | Verve Therapeutics, Inc. | 132 | 2024-10-30 | 2026-10-23 |
| A Study on Evaluating the Safety of HST101 in Healthy Chinese Participants HST101 - Hypercholesterolemia, Healthy Volunteers | Phase 1 | Enrolling by invitation | Hasten Biopharmaceutical Co., Ltd. | 30 | 2024-09-17 | 2025-03-14 |
| A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias CTX310 - Cardiovascular, Metabolic Disease | Phase 1 | Recruiting | CRISPR Therapeutics AG | 90 | 2024-06-21 | 2026-09-18 |
| Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020) Enlicitide Decanoate - Hypercholesterolaemia | Phase 1 | Completed | Merck Sharp & Dohme LLC | 33 | 2023-07-20 | 2026-09-30 |
| A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin. AZD0780, Rosuvastatin - Dyslipidemia | Phase 1 | Completed | AstraZeneca | 16 | 2023-03-09 | 2025-04-27 |
| A Study to Investigate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 Administered IM in Adult Participants VXX-401, Placebo - Hypercholesterolemia | Phase 1 | Completed | Axxium Life, Inc. | 64 | 2023-03-07 | 2026-11-04 |
| A Study of MK-0616 in Healthy Adult Participants (MK-0616-009) MK-0616 - Hypercholesterolemia | Phase 1 | Completed | Merck Sharp & Dohme LLC | 24 | 2022-10-25 | 2024-09-19 |
| A Study of Enlicitide Chloride (MK-0616) in Healthy Participants and Participants Taking Statins (MK-0616-012) Enlicitide Chloride, Placebo - Healthy, Hypercholesterolemia | Phase 1 | Completed | Merck Sharp & Dohme LLC | 56 | 2022-09-30 | 2024-10-23 |
| A Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1018-1 and BR1018-2 in Healthy Adult Subjects BR1018-1, BR1018-2 - Hypertension, Hyperlipidemia (E.G., Hypercholesterolemia) | Phase 1 | Completed | Boryung Pharmaceutical Co., Ltd | 36 | 2022-08-04 | 2023-05-24 |
| A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease VERVE-101 - Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease | Phase 1 | Completed | Verve Therapeutics, Inc. | 13 | 2022-07-05 | 2025-05-08 |
Showing 20 of 105. Sign in to see all of them.
Dyslipidemias (19) · Hyperlipidemias (18) · Atherosclerosis (8) · Hypertension (7) · Cardiovascular Diseases (6) · Lipid Metabolism Disorders (5) · Metabolic Diseases (5) · Hyperlipoproteinemia Type II (4) · Hypertriglyceridemia (4) · Coronary Artery Disease (3) · Diabetes Mellitus (3) · Obesity (3) · Aneurysm (2) · Diabetes Mellitus, Type 2 (2)
Nutritional and Metabolic Diseases (104) · Lipid Metabolism Disorders (100) · Metabolic Diseases (100) · Hyperlipidemias (87) · Dyslipidemias (86) · Vascular Diseases (14) · Cardiovascular Diseases (12) · Arterial Occlusive Diseases (10) · Arteriosclerosis (10) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Endocrine System Diseases (5) · Genetic Diseases, Inborn (5) · Glucose Metabolism Disorders (5) · Pathological Conditions, Signs and Symptoms (5) · Heart Diseases (4)
alirocumab (10) · Ezetimibe (8) · Atorvastatin (6) · bococizumab (6) · Rosuvastatin Calcium (5) · Simvastatin (4) · 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (3) · MK-0616 (3) · gemcabene (3) · Drug Evaluation (2) · Niacin (2) · Sodium Chloride (2) · 3,5-diiodothyropropionic acid (1) · ALN-PCS (1) · Adjuvants, Pharmaceutic (1)
Pfizer (11) · Sanofi (9) · Merck Sharp & Dohme LLC (6) · AstraZeneca (5) · Jiangsu HengRui Medicine Co., Ltd. (3) · NeuroBo Pharmaceuticals Inc. (3) · Novartis Pharmaceuticals (3) · Novo Nordisk A/S (3) · Organon and Co (3) · AJU Pharm Co., Ltd. (2) · Bristol-Myers Squibb (2) · GlaxoSmithKline (2) · Humanis Saglık Anonim Sirketi (2) · National Heart, Lung, and Blood Institute (NHLBI) (2) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (2)
United States (39) · United Kingdom (10) · China (9) · Australia (8) · Canada (6) · Germany (6) · Belgium (4) · France (3) · India (3) · Netherlands (3) · New Zealand (3) · South Korea (3) · Brazil (2) · Austria (1) · Israel (1)
Werner Siegmund, Prof (2) · Adrian Di Bisceglie, MD,FACP,FAASLD (1) · Annabelle Rodriguez, MD (1) · Brad West, ND (1)
PMID 37994400, PMID 28181260, PMID 40587053, PMID 15324521, PMID 18068514, PMID 19500003, PMID 19833861, PMID 19843338, PMID 20457158, PMID 21120461, PMID 21417623, PMID 22435370, PMID 25256660, PMID 25942458, PMID 26261033, PMID 26607938, PMID 27184170, PMID 27287699, PMID 27959715, PMID 27986651, PMID 28636184, PMID 29037448, PMID 29844318, PMID 30243503, PMID 30623096, PMID 32080823, PMID 33183320, PMID 33969434, PMID 35427476, PMID 35795564, PMID 40252193, PMID 42137960
2015 (3), 2009 (1), 2019 (1), 2025 (1)